You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 22, 2024

GLYRX-PF Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard


When do Glyrx-pf patents expire, and when can generic versions of Glyrx-pf launch?

Glyrx-pf is a drug marketed by Exela Pharma and is included in one NDA.

The generic ingredient in GLYRX-PF is glycopyrrolate. There are seventeen drug master file entries for this compound. Fifty-six suppliers are listed for this compound. Additional details are available on the glycopyrrolate profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Glyrx-pf

A generic version of GLYRX-PF was approved as glycopyrrolate by AM REGENT on July 23rd, 1986.

  Sign Up

AI Research Assistant
Questions you can ask:
  • What is the 5 year forecast for GLYRX-PF?
  • What are the global sales for GLYRX-PF?
  • What is Average Wholesale Price for GLYRX-PF?
Summary for GLYRX-PF
Drug patent expirations by year for GLYRX-PF
Drug Prices for GLYRX-PF

See drug prices for GLYRX-PF

Pharmacology for GLYRX-PF
Drug ClassAnticholinergic
Mechanism of ActionCholinergic Antagonists

US Patents and Regulatory Information for GLYRX-PF

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Exela Pharma GLYRX-PF glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 210997-001 Jul 11, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exela Pharma GLYRX-PF glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 210997-003 Apr 9, 2020 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exela Pharma GLYRX-PF glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 210997-002 Jul 11, 2018 RX Yes Yes ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
Exela Pharma GLYRX-PF glycopyrrolate SOLUTION;INTRAMUSCULAR, INTRAVENOUS 210997-004 Dec 14, 2020 DISCN Yes No ⤷  Sign Up ⤷  Sign Up ⤷  Sign Up
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.